analyst
-
Goldman Neutral On Stryker (SYK)
Goldman Sachs has a Neutral rating on Stryker Corp. (NYSE: SYK) after the company announced a sale of a division. In a note…
Read More » -
Integra Lifesciences M&A Unlikely Until 2011, Citigroup Reports
Integra Lifesciences Holdings (NASDAQ: IART) management has not undertaken a deal in over a year, and even though a transaction in…
Read More » -
Deutsche Bank Maintains Hold Rating of Stryker and Zimmer
As the market becomes highly focused on monthly trends in an effort to understand whether things are getting better or…
Read More » -
NuVasive Poised For Strong Results
Nuvasive Inc. (NYSE: NUVA) plans on holding an analyst meeting on September 14. According to Jefferies, while there may be doubt…
Read More » -
Biggest ever hip fracture audit shows improvements in care, but significant geographical variations
A report from the world’s largest and fastest-growing national hip fracture audit, published today (Thursday 2nd September) reveals that NHS…
Read More » -
Canaccord Genuity Reiterates a ‘Buy’ Rating on Exactech (EXAC); Silverbolt Acquisition Adds Fifferentiated MIS Product
Canaccord Genuity reiterates a ‘Buy’ rating on Exactech, Inc. (Nasdaq: EXAC), lowers PT from $26 to $23.50. Canaccord analyst says, “We…
Read More » -
Orthopaedic Industry Expected to Continue to Grow in Mid to High Single Digit Range Despite Healthcare ‘Reform’
CHAGRIN FALLS, Ohio, June 16 /PRNewswire/ — Renowned orthopaedic industry expert Shirley A. Engelhardt kicked off the 6th Annual Orthopaedic Manufacturing & Technology Exposition…
Read More » -
Research and Markets: U.S. Market for Orthopedic Biomaterials 2010
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/9f7d82/u_s_market_for_or) has announced the addition of the “U.S. Market for Orthopedic Biomaterials 2010” report to their…
Read More » -
Medtronic Beats Zacks Ests
Medtronic, Inc. (MDT – Analyst Report) reported fourth quarter fiscal 2010 earnings per share of 89 cents, beating the Zacks Consensus…
Read More » -
Needham & Company Reiterates a ‘Strong Buy’ on NuVasive (NUVA)
Needham & Company reiterates a ‘Strong Buy’ rating on NuVasive Inc. (Nasdaq: NUVA), price target $60. Needham analyst says, “We expect…
Read More » -
Wells Fargo Upgrades Orthofix International N.V. (OFIX) to Outperform
Wells Fargo upgrades Orthofix International N.V. (Nasdaq: OFIX) to Outperform. Valuation range increased from $33-38 to $39-43. Wells analyst says, “We…
Read More » -
Regenerative Medicine to Be a $20 Billion Industry by 2025
April 22, 2010 by Brendon Nafziger, Writer Explosive growth over the next decade in the field of regenerative medicine could aid…
Read More » -
Needham & Company Reiterates a ‘Strong Buy’ on NuVasive (NUVA)
April 19, 2010 8:03 AM EDT Needham & Company reiterates a ‘Strong Buy’ rating on NuVasive Inc. (Nasdaq: NUVA), price target…
Read More » -
NuVasive (NUVA) Showing 30% to 35% Revenue Growth In 2010; Introduction Of Lateral Access Spine Surgery Critical To Operations
April 19, 2010 – The Wall Street Transcript has just published Medical Devices Reportoffering a timely review of the Health Services…
Read More » -
Zimmer Upped to Neutral
We recently upped Zimmer Holdings, Inc. (ZMH – Analyst Report) to ‘Neutral’ with a target price of $61 based on a P/E…
Read More »